Abstract
Recombinant interleukin-2 (rIL-2) is a new promising treatment for cancer, but is associated with severe renal toxicity. This study is the first to analyse the renal effects of rIL-2 in children. Twenty-one cycles of continuous rIL-2 infusion were studied in 15 patients; mean age was 6.9 years and average weight 18.9 kg. Interstitial fluid retention and oliguria (baseline, 1.7 ml/kg per hour; nadir, 0.5 mg/kg per hour) were associated with hypotension (baseline, 101/56 mm Hg; nadir, 85/43 mm Hg) and decreased intravascular volume (plasma renin activity increased×10). Weight gain (+7.9%) was observed in 13 cycles whereas weight loss (−6.3%) was shown in 8 cycles because of digestive and cutaneous losses, mainly in the youngest patients. This prerenal azotaemia was characterized by a decrease in creatinine clearance (from 101 to 36 ml/min per 1.73 m2) and a low fractional excretion and sodium (FENa) (from 0.70% to 0.09%).Hypotension and hypovolaemia needed vascular filling (n=12), dopamine (n=7) and interruption of rIL-2 (n=2). Most abnormalities occurred as early as day 2 of therapy and were always reversible after a short period with sodium leakage (diuresis=2.2 ml/kg per hour, FENa=2.01%). Hypophosphataemia was associated with low urinary excretion of phosphorus, suggesting an increased uptake of inorganic phosphorus by rapidly proliferating lymphoid cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897
Rosenberg SA (1989) Clinical immunotherapy studies in the Surgery Branch of the US National Cancer Institute: brief review. Cancer Treat Rev 16 [Suppl A]: 115–121
Sculier JP, Bron D, Verboven N, Klastersky J (1988) Multiple organ failure during interleukin 2 administration and LAK cells infusion. Intensive Care Med 14:666–667
Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735–1739
Favrot M, Floret D, Michon J, Negrier S, Bouffet E, Coze C, Gaspard M, Cochat P, Thiesse P, Andreu G, Costil J, Zucker JM, Bernard JL, Fridman WH, Mathiot C, Bijmann JT, Francks CR, Kremens B, Philip I, Philip T (1989) A phase II study of adoptive immunotherapy with continuous infusion of interleukin 2 in children with advanced neuroblastoma.A report of 11 cases. Cancer Treat Rev 16 [Suppl A]: 129–142
Michie HR, Eberlein TJ, Spriggs DR, Manogue KR, Cerami A, Wilmore DW (1988) Interleukin-2 initiates metabolic responses associated with critical illness in humans. Ann Surg 208: 493–501
Belldegrun A, Webb DE, Austin HA III, Steinberg SM, White DE, Linehan WM, Rosenberg SA (1987) Effects of interleukin 2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106: 817–820
Webb DE, Austin HA III, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA (1988) Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 30: 141–145
Cochat P, Brunet J, Philip T, Floret D, Wright C, Bouffet E, David L, Favrot M (1988) Nephrotoxicity of treatment by interleukin-2 in children with neuroblastoma. Pediatr Nephrol 2: C120
Lagrue G, Heslan JM, Pech MA, Branellec A, Rostoker G, Lang P (1987) L'interleukin-2 joue-t-elle un rôle dans la protéinurie des syndromes néphrotiques idiopathiques? Nephrologie8: 312
Hisanaga S, Kawagoe H, Yamamoto Y, Kurori N, Fujimoto S, Tanaka K, Kurokawa M (1990) Nephrotic syndrome associated with recombinant interleukin 2. Nephron 54: 277–278
Isner JM, Dietz WA (1988) Cardiovascular consequences of recombinant DNA technology: interleukin 2. Ann Intern Med 109: 933–935
Revhaug A, Michie HR, Manson JMcK (1988) Inhibition of cyclooxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg 123: 162–170
Sato N, Goto T, Haranaka K (1986) Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst 76: 1113–1121
Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ (1988) Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 319: 761–767
Hart D, Lifschitz MD (1987) Renal physiology of the prostaglandins and the effects of non steroidal anti-inflammatory agents on the kidney. Am J Nephrol 7: 408–418
Bock HA, Frölich JC, Ritz R, Brunner FP (1986) Effects of intravenous aspirin on prostaglandin synthesis and kidney function in intensive care patients. Nephrol Dial Transplant 1: 164–169
West WH, Taver KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldhan RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905
Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA (1987) Reduction of toxicity of interleukin 2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5: 496–500
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cochat, P., Floret, D., Bouffet, E. et al. Renal effects of continuous infusion of recombinant interleukin-2 in children. Pediatr Nephrol 5, 33–37 (1991). https://doi.org/10.1007/BF00852838
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00852838